29 Jun Diabetes: Comparative Effectiveness of SGLT2I vs Sulfonylureas All-Cause Mortality.
MedicalResearch.com Interview with:
Dr. Ziyad Al-Aly
Dr. Ziyad Al-Aly, MD, FASN
Clinical Epidemiology Center
Research and Development Service
Veterans Affairs St. Louis Health Care System
St. Louis, MO
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: There are several randomized controlled trials of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) but none (not a single study) provided a head-to-head comparison with sulfonylureas — the most commonly prescribed antihyperglycemics after metformin.
We resolved to leverage advanced methodologies to undertake a head-to-head investigation of the comparative effectiveness of SGLT2I vs sulfonylureas on the risk of all-cause mortality.
MedicalResearch.com: What should readers take away from your report?
Response: In people with diabetes already on metformin, initiation of SGLT2i was associated with lower risk of all-cause mortality compared with initiation of sulfonylureas.
This effect was evident regardless of cardiovascular disease status, regardless of albuminuria and eGFR.
Continued use of SGLT2i + metformin was superior to using SGLT2i alone (this is important as a lot of people are using SGLT2i alone and skipping metformin).
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: Clinical practice and guidelines should be informed by evidence. There is a tendency to skip metformin and jump into SGLT2i immediately. I think our results provide evidence that combined use of SGLT2i + metformin is better than SGLT2i alone. I think this area deserves more examination.
No disclosures
Citations:
Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Al-Aly Z. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. JAMA Intern Med. Published online June 28, 2021. doi:10.1001/jamainternmed.2021.2488
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on June 29, 2021 by Marie Benz MD FAAD